e l f Beauty Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2× e l f Beauty Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Halozyme Therapeutics Inc. Common Stock for 0 Days on average.
| ELF | HALO | |
|---|---|---|
Market Cap | $6.20B | $12.58B |
Volume | 1,301,240 | 2,179,278 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $115.22 |
52-Week Low | $49.57 | $61.63 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $6.78B | $14.49B |
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →